The riff on Apple’s Mac versus PC campaign lightens the pharma tone while also leaning more into disclosures.

AI’s growing clout in healthcare and pharma and candid confessions from drugmaker CEOs dominated the narrative at JPM 2026.

The change could ease stigma and fuel uptake, especially as oral weight loss drugs hit the market.

Novo and Lilly prohibit telehealth partners from offering compounded GLP-1s, eroding compounders’ ability to distribute.

The first oral GLP-1 hits pharmacy shelves and telehealth platforms this week, expanding access to more affordable obesity treatment.

As more Americans take weight loss drugs, eating, shopping, and healthcare expectations are all evolving

Pharma’s intangible value drops as others climb: While other sectors gained ground, pharma lost value, driven by individual company setbacks and policy pressures.

Pharma, startups, and the federal government piled into virtual care with new platforms and partnerships.

Wegovy pill offers a needle-free, lower-cost option that could broaden patient access.

Pharma companies see pricing concessions as the lesser of two evils, as the price cuts grant exemption from Trump’s tariffs on US drug imports.

Lilly and Novo gear up to market oral obesity drugs, expected to reshape the growing market with a less-invasive way to meet weight loss demand in pharma.

Hims & Hers is officially bringing its subscription weight loss program to the UK. But rising prices of some GLP-1 medications in the UK may lower the incentive for consumers to sign up for a membership with a telehealth company offering prescriptions.

Structure Therapeutics’ experimental obesity pill led to an average 12.1% weight loss after 36 weeks on a 120 mg daily dose, which stacks up well against competitors. Newcomers to the weight loss drug market still face key disadvantages, even with strong trial results. For smaller weight loss drug developers that may not have the risk appetite or resources to compete with larger players, the best way to cash in on a market dominated by two giants may be to pursue a partnership or acquisition.

Among patients newly prescribed GLP-1s for obesity, 90% either never start therapy or discontinue within a year. Novo and Lilly are using their direct-to-consumer online pharmacies to improve adherence, giving them clearer insight into why patients don’t fill or refill prescriptions to offer targeted support. Beyond that, drugmakers should work with their telehealth partners and pharmacies to give patients resources on managing side effects, navigating insurance issues, and understanding why maintenance dosing remains important after achieving some weight loss.

Eli Lilly is dropping the price of its weight loss drug Zepbound for cash-pay customers, following rival Novo Nordisk’s price cut less than two weeks ago. Lilly and Novo’s newly lowered D2C prices will help some cash-pay consumers, but the affordability gap is a major barrier to broader adoption.

Novo Nordisk has applied for approval of a higher-dose version of its weight loss drug Wegovy using a special FDA review pathway for a faster decision. Novo’s move to introduce a higher-dose Wegovy shifts competitive expectations in the weight loss category in terms of speed and effectiveness, with over 20% weight loss becoming the new benchmark for success.

The Trump administration announced lower Medicare prices for 15 prescription drugs via the Medicare drug price negotiation program. The new prices will take effect starting January 1, 2027. The biggest hit will fall on pharma companies with drugs selected in both rounds of Medicare negotiations. Revenue impacts will vary depending on each product’s time on the market and how far the negotiated price falls below prior net sales after rebates and discounts. For the government, savings on these drugs will be significant, but broader program savings won’t materialize until far more than 25 drugs see price cuts.

Novo Nordisk’s GLP-1 drug semaglutide failed to slow the progression of Alzheimer’s disease in new study results, dashing hopes that GLP-1s might one day be approved to treat the condition. Novo’s Alzheimer’s results underscore the boundary of how far GLP-1s can stretch beyond metabolic diseases.

Eli Lilly became the first healthcare or pharma company to reach a $1 trillion valuation. Pharma’s entry into “the trillion-dollar club” is largely driven by success in the obesity treatment category that’s poised to reshape consumer health and wellness. However, Lilly’s particular rapid growth signals that while first-mover advantage in a high-demand disease area matters, it doesn’t guarantee staying on top. Pharma manufacturers can make up for not being first by committing to innovative drug development that drives more efficacious products, pursuing new clinical indications, and correctly anticipating market developments that may impact supply and demand.

Starting next year, Novo Nordisk and Eli Lilly will sell their weight loss shots directly to employers, cutting out pharmacy benefit managers, per Bloomberg. This move further signals drugmakers’ push into direct sales, both to consumers and employers. More businesses will likely cover obesity drugs for their workers if they can achieve greater cost control of their offered benefits. And pharma supply chain middlemen could feel mounting pressure to shift further away from the prescription drug rebate model that so many in the industry decry.